Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

Status Enrolling by invitation

Clinical Trial Summary

This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the long-term efficacy and prognosis risk factors of autologous stem cell transplantation for the treatment of AL amyloidosis.

Clinical Trial Description

This study is divided into two parts. In the first part, the investigators retrospectively analyze the data of patients with AL amyloidosis who treated with autologous stem cell transplantation from July 2010 to December 2019. All patients had a biopsy-proven disease by positive Congo red stain with a concomitant demonstration of plasma cell dyscrasia. Organ involvement was established according to the criteria established at the 10th International Symposium on Amyloid and Amyloidosis. The protocol of ASCT included mobilization with colony-stimulating factor alone and conditioning with high-dose melphalan 140 or 200 mg/m2. In addition to analyzing the efficacy and safety of all the patients, the investigators also analyzed the difference in efficacy between patients in different subgroups. For example, subgroups divided according to different induction treatment regimens; subgroups divided according to different plasma cell FISH data and FCM data; subgroups divided according to the degree of organ involvement, and subgroups divided according to different maintenance treatment regimens. In the second part of the study, the investigators will conduct a prospective study to explore the best autologous stem cell transplantation treatment protocol for AL amyloidosis. The protocol includes the induction therapy with bortezomib and daratumumab before ASCT, the maintenance treatment with lenalidomide after ASCT, and the treatment options for recurrence after transplantation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04210791
Study type	Observational [Patient Registry]
Source	Nanjing University School of Medicine
Contact
Status	Enrolling by invitation
Phase
Start date	July 1, 2010
Completion date	December 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05451771` - Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	Phase 1/Phase 2
Completed	`NCT02574676` - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Active, not recruiting	`NCT05199337` - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Completed	`NCT01409148` - Radioimmunoimaging of AL Amyloidosis	Phase 1
Active, not recruiting	`NCT04512235` - A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis	Phase 3
Recruiting	`NCT06383143` - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Recruiting	`NCT05277493` - A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
Completed	`NCT02632786` - The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis	Phase 2
Completed	`NCT02841033` - Daratumumab for the Treatment of Patients With AL Amyloidosis	Phase 1/Phase 2
Completed	`NCT04304144` - A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis	Phase 2
Recruiting	`NCT01408225` - Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Recruiting	`NCT04895917` - Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis	Phase 2
Terminated	`NCT02489500` - Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib	Phase 3
Completed	`NCT01570387` - A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis	Phase 1/Phase 2
Terminated	`NCT03154047` - Study in Subjects With Light Chain (AL) Amyloidosis	Phase 2
Completed	`NCT03236792` - Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT04392960` - Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis	N/A
Recruiting	`NCT05898646` - Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial	Phase 2